Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4306506 | 0.92 | ALDH1A1 (0.39) | ALDH1A1MAPK1KMT2ASCN9ASCN5A | |
| SCHEMBL22738226 | 0.91 | SCN9A (0.38) | ALDH1A1MAPK1KMT2ASCN9ASCN5A | |
| SCHEMBL30193078 | 0.87 | KMT2A (0.40) | ALDH1A1MAPK1KMT2AMAOB | |
| SCHEMBL1503189 | 0.87 | KMT2A (0.40) | ALDH1A1MAPK1KMT2AMAOB | |
| SCHEMBL22719950 | 0.82 | MAOB (0.39) | ALDH1A1MAPK1KMT2AMAOB | |
| SCHEMBL2146871 | 0.80 | MAPT (0.38) | ALDH1A1KMT2AMAOBHTR1AADRA1A | |
| SCHEMBL2147119 | 0.79 | ALDH1A1 (0.36) | ALDH1A1MAPK1KMT2AMAOB | |
| SCHEMBL24065373 | 0.78 | MAPK1 (0.41) | MAPK1PPARG | |
| SCHEMBL12398991 | 0.78 | KMT2A (0.48) | ALDH1A1MAPK1KMT2AMAOB | |
| SCHEMBL22719944 | 0.78 | HDAC1 (0.36) | ALDH1A1MAPK1KMT2AMAOBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | claimed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | claimed |
| EP-3687538-B1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INST (CA) | 2024-04-17 | — | — | EP | disclosed |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2024-03-19 | — | — | US | disclosed |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | Montréal Heart Institute (CA) | 2023-03-23 | — | — | US | disclosed |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2022-08-02 | — | — | US | disclosed |
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INSTITUTE (CA) | 2021-12-02 | — | — | US | disclosed |
| EP-3687538-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | Montreal Heart Institute (CA) | 2020-08-05 | — | — | EP | disclosed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| EP-2300433-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | Ambrilia Biopharma Inc. (CA) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | ALDH1A1 568/4885MAPK1 2839/4885KMT2A 4239/4885 |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | PNPO, CCNB1, BLVRB | ALDH1A1 334/4885MAPK1 1638/4885KMT2A 1953/4885 |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | ALDH1A1 568/4885MAPK1 2839/4885KMT2A 4239/4885 |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | ALDH1A1 568/4885MAPK1 2839/4885KMT2A 4239/4885 |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | ALDH1A1 568/4885MAPK1 2839/4885KMT2A 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.